ANIX Should I Buy

• Not a good buy right now for an impatient investor: trend structure is still bearish (SMA_200 > SMA_20 > SMA_5) and price is below the 3.118 pivot, suggesting rallies may fail near resistance.
• Options positioning is extremely call-heavy and IV is very elevated, which can support short-term spikes but also implies expensive/overheated expectations rather than a clean low-risk entry.
• Near-term upside catalysts are mostly “story/progress” (drug naming approvals) rather than value-changing clinical data; fundamentals remain pre-revenue with widening losses.

Intellectia Proprietary Trading Signals

• AI Stock Picker: no signal on given stock today.
• SwingMax: No signal on given stock recently.

• Pre-market price: 3.04, trading below Pivot 3.118; this keeps the immediate bias cautious until reclaiming ~3.12.
• Moving averages: Bearish alignment (SMA_200 > SMA_20 > SMA_5) indicates the broader trend is still down.
• MACD histogram: +0.0104 and expanding above zero, showing improving momentum (early rebound attempt), but not enough yet to negate bearish MA structure.
• RSI(6): 43.34 (neutral-to-soft), not signaling an oversold bounce.
• Key levels: Support S1 2.946 then S2 2.84; Resistance R1 3.29 then R2 3.396. A push above 3.29 would improve the short-term setup; loss of 2.95 increases downside risk.
• Pattern-based projection (similar candles): modest positive drift expectations (+0.52% next day, +1.05% next week, +5.53% next month), but this is not confirmed by trend structure yet.